Log in

NYSEAMERICAN:PTNPalatin Technologies Stock Price, Forecast & News

$0.52
-0.03 (-4.99 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.52
Now: $0.52
$0.58
50-Day Range
$0.87
MA: $0.93
$1.06
52-Week Range
$0.36
Now: $0.52
$1.78
Volume2.26 million shs
Average Volume1.49 million shs
Market Capitalization$119.54 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL­3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Read More
Palatin Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PTN
CUSIPN/A
Phone+1-609-4952200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees19
Market Cap$119.54 million
Next Earnings Date9/10/2020 (Estimated)
OptionableNot Optionable

Receive PTN News and Ratings via Email

Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter.

Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Palatin Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Palatin Technologies.

When is Palatin Technologies' next earnings date?

Palatin Technologies is scheduled to release its next quarterly earnings announcement on Thursday, September 10th 2020. View our earnings forecast for Palatin Technologies.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). During the same quarter last year, the firm posted ($0.03) EPS. View Palatin Technologies' earnings history.

What price target have analysts set for PTN?

2 equities research analysts have issued 1-year price targets for Palatin Technologies' shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate Palatin Technologies' stock price to reach $4.00 in the next year. This suggests a possible upside of 667.2% from the stock's current price. View analysts' price targets for Palatin Technologies.

Has Palatin Technologies been receiving favorable news coverage?

Media stories about PTN stock have been trending negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Palatin Technologies earned a news impact score of -2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutPalatin Technologies.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 15,870,000 shares, a decline of 8.3% from the March 31st total of 17,300,000 shares. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is currently 10.7 days. Approximately 7.4% of the company's shares are short sold. View Palatin Technologies' Current Options Chain.

Who are some of Palatin Technologies' key competitors?

What other stocks do shareholders of Palatin Technologies own?

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the following people:
  • Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 65)
  • Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 57)
  • Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 62)
  • Burns McClellan, VP of Investor Relations

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.70%), Acadian Asset Management LLC (2.37%), State Street Corp (1.61%), Geode Capital Management LLC (1.25%), WINTON GROUP Ltd (0.33%) and Bank of New York Mellon Corp (0.27%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View institutional ownership trends for Palatin Technologies.

Which institutional investors are selling Palatin Technologies stock?

PTN stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, BlackRock Inc., Morgan Stanley, UBS Group AG, First Trust Advisors LP, and Banque Cantonale Vaudoise. View insider buying and selling activity for Palatin Technologies.

Which institutional investors are buying Palatin Technologies stock?

PTN stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Geode Capital Management LLC, Wells Fargo & Company MN, State Street Corp, Parametric Portfolio Associates LLC, JPMorgan Chase & Co., Two Sigma Advisers LP, and SG Americas Securities LLC. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr, and Stephen T Wills. View insider buying and selling activity for Palatin Technologies.

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $0.52.

How big of a company is Palatin Technologies?

Palatin Technologies has a market capitalization of $119.54 million. Palatin Technologies employs 19 workers across the globe.

What is Palatin Technologies' official website?

The official website for Palatin Technologies is www.palatin.com.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.